pharmaceuticals « Science and Enterprise

New Venture Funds to Back Life Science, Tech Start-Ups

By Alan, on January 26th, 2023%

Three new venture funds are seeking to invest up to $6.3 billion in start-up companies with advances in life sciences, health care, energy, and information technologies. . . . → Read More: New Venture Funds to Back Life Science, Tech Start-Ups

Real-World Data Shown to Match Eye Disease Trial Results

By Alan, on January 19th, 2023%

Research findings show data in patients’ electronic health records can be collected and analyzed to replicate results from late-stage clinical trials of an eye disease biologic drug. . . . → Read More: Real-World Data Shown to Match Eye Disease Trial Results

Nasal Spray Vaccine Shown to Stop Gonorrhea Infections

By Alan, on January 16th, 2023%

A vaccine against gonorrhea given as a nasal spray is shown to generate protective immune responses in lab mice of both sexes, and in females similar to an intravaginal vaccine. . . . → Read More: Nasal Spray Vaccine Shown to Stop Gonorrhea Infections

Infographic – 2022 Biotech Venture Funding Weakens

By Alan, on January 14th, 2023%

Chart: Venture investments total by year for biotech and pharma companies

Venture funds for new U.S. biotechnology and pharmaceutical companies declined from historical highs in 2022, but a closer look reveals even more signs of financial tightening. . . . → Read More: Infographic – 2022 Biotech Venture Funding Weakens

CEPI Assessing Advanced RNA Nanoparticle Vaccine

By Alan, on January 12th, 2023%

An international health organization is evaluating a new type of vaccine made with biodegradable RNA nanoparticles to help head off future viral pandemics. . . . → Read More: CEPI Assessing Advanced RNA Nanoparticle Vaccine

Nanotech Enzyme Process Boosts T-Cell Cancer Therapies

By Alan, on January 10th, 2023%

A bioengineering team devised techniques for feasibly adding cancer-killing enzymes to engineered immune cells that in lab mice kill solid-tumor and blood cancer cells. . . . → Read More: Nanotech Enzyme Process Boosts T-Cell Cancer Therapies

BioNTech to Provide Personal Cancer Immunotherapies in UK

By Alan, on January 6th, 2023%

The biotechnology company BioNTech SE is partnering with the U.K. government to provide up to 10,000 personalized cancer immunotherapy treatments by 2030. . . . → Read More: BioNTech to Provide Personal Cancer Immunotherapies in UK

Biotech Alliance Creating Circular RNA Cancer Drug

By Alan, on January 5th, 2023%

A partnership of biotechnology components and therapy companies aims to develop new drugs made from circular forms of RNA, starting with a colorectal cancer treatment. . . . → Read More: Biotech Alliance Creating Circular RNA Cancer Drug

Protein Chemistry Biotech Gains Collaboration, Venture Funds

By Alan, on January 4th, 2023%

An enterprise discovering new drugs with optical light-based protein chemistry is emerging from stealth, including work with biopharmaceutical company Genentech. . . . → Read More: Protein Chemistry Biotech Gains Collaboration, Venture Funds

Trial Shows Anti-Inflammatory Drug Stops Covid-19 Hospitalization

By Alan, on January 3rd, 2023%

Findings from a clinical trial show an anti-inflammatory drug reduces new symptoms among people with Covid-19 infections and keeps them out of the hospital. . . . → Read More: Trial Shows Anti-Inflammatory Drug Stops Covid-19 Hospitalization

Subscribe for email alerts

Donate to Science & Enterprise

Like us on Facebook

S&E on Mastodon

S&E on LinkedIn

Posts RSS feed

Specials

Guest Posts

Please share Science & Enterprise